Cancer Stem Cells: Models and Concepts

Annual Review of Medicine - Tập 58 Số 1 - Trang 267-284 - 2007
Piero Dalerba1, Robert W. Cho2, Michael F. Clarke2
1Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California 94304, USA. [email protected]
2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California 94304;, ,

Tóm tắt

Although monoclonal in origin, most tumors appear to contain a heterogeneous population of cancer cells. This observation is traditionally explained by postulating variations in tumor microenvironment and coexistence of multiple genetic subclones, created by progressive and divergent accumulation of independent somatic mutations. An additional explanation, however, envisages human tumors not as mere monoclonal expansions of transformed cells, but rather as complex tridimensional tissues where cancer cells become functionally heterogeneous as a result of differentiation. According to this second scenario, tumors act as caricatures of their corresponding normal tissues and are sustained in their growth by a pathological counterpart of normal adult stem cells, cancer stem cells. This model, first developed in human myeloid leukemias, is today being extended to solid tumors, such as breast and brain cancer. We review the biological basis and the therapeutic implications of the stem cell model of cancer.

Từ khóa


Tài liệu tham khảo

10.1016/j.cell.2006.03.011

10.1038/35102167

10.1016/0092-8674(90)90186-I

10.1007/s00280-005-0097-1

10.2307/3570892

10.1146/annurev.immunol.21.120601.141007

10.1126/science.2898810

10.1016/1074-7613(94)90037-X

Morrison SJ, 1997, Development, 124, 1929, 10.1242/dev.124.10.1929

10.1016/j.cell.2005.05.026

10.1073/pnas.2034201100

10.1002/stem.5530150826

10.1073/pnas.94.10.5320

10.1073/pnas.172384399

10.1182/blood.V77.6.1218.1218

10.1073/pnas.89.7.2804

10.1146/annurev.med.54.101601.152334

10.1182/blood.V58.5.916.916

10.1016/0002-9343(77)90124-3

10.1056/NEJM197610212951702

10.1182/blood.V57.6.1068.1068

10.1038/nm0797-730

10.1038/367645a0

10.1182/blood.V85.8.2154.bloodjournal8582154

10.1073/pnas.97.13.7521

10.1182/blood.V89.9.3104

10.1001/jama.294.11.1359

10.1182/blood.V92.12.4758

10.1111/j.1365-2141.2005.05944.x

10.1056/NEJMoa040258

10.1056/NEJMp048120

10.1182/blood.V91.4.1216

10.1038/nature01587

10.1093/emboj/17.13.3714

10.1038/nature01572

10.1016/S0092-8674(00)80674-1

10.1038/nature04703

10.1038/nature04747

10.1158/0008-5472.CAN-04-3678

10.1038/nature04372

10.1038/nature04496

10.1136/gut.2003.025478

10.1093/carcin/21.3.469

Seery JP, 2002, J. Cell Sci, 115, 1783, 10.1242/jcs.115.9.1783

10.1016/S0959-437X(00)00211-2

10.1016/j.ceb.2003.10.012

10.1073/pnas.1734203100

10.1016/j.cell.2005.03.032

10.1002/path.1160

10.1111/j.1479-828X.2004.00290.x

10.1098/rstb.1998.0246

10.1016/S0090-4295(03)00758-1

10.1146/annurev.neuro.28.051804.101459

10.1016/j.cell.2005.05.010

10.1073/pnas.0511137103

10.1073/pnas.0530291100

10.1007/s10911-005-2540-7

10.1101/gad.1061803

10.1158/0008-5472.CAN-05-0626

10.1158/0008-5472.CAN-04-1364

Singh SK, 2003, Cancer Res., 63, 5821

10.1038/nature03128

10.1038/nrc1889

10.1158/0008-5472.CAN-05-2018

10.1038/sj.onc.1209327

10.1158/0008-5472.CAN-05-1343

10.1073/pnas.0502320102

10.1182/blood-2003-09-3064

10.1038/nrc1694

10.1093/carcin/bgi044

10.1073/pnas.171610498

10.1007/s00418-004-0645-5

10.1016/S0092-8674(00)81683-9

10.1093/carcin/bgh296

10.1038/sj.onc.1205163

10.1016/S1074-7613(00)80316-7

Dimri GP, 2002, Cancer Res., 62, 4736

10.1002/1096-9896(2000)9999:9999<::AID-PATH728>3.0.CO;2-G

10.1038/sj.onc.1207113

10.1016/0959-8049(92)90468-H

Khan ZA, 2000, Clin. Cancer Res., 6, 3499

10.1136/mp.56.3.137

10.1023/B:CLIN.0000017206.08931.42

10.1002/(SICI)1097-0215(19980717)77:2<200::AID-IJC5>3.0.CO;2-U

10.1002/ijc.20883

10.1073/pnas.2634067100

10.1038/nrc1670

10.1182/blood-2002-10-3062

10.1073/pnas.252462599

10.1016/j.gde.2003.11.007

10.1016/S1040-8428(02)00159-2

10.1093/jnci/94.11.805